Lorundrostat - (Transform-HTN)

September 23, 2026: Mineralys Therapeutics (NASDAQ: MLYS) announced that late-breaking long-term efficacy and safety data from the ongoing Transform-HTN open-label extension trial of lorundrostat will be presented at the American Heart Association Scientific Sessions 2026 in Chicago. The presentation is scheduled for November 8, 2026, at 3:30 p.m. CT.

Transform-HTN (NCT05968430) is a global open-label extension study evaluating the safety, efficacy, and tolerability of lorundrostat in hypertension patients who completed one of three parent studies: Advance-HTN, Launch-HTN, or Explore-CKD. The trial’s primary endpoint is change in automated office systolic blood pressure.

Lorundrostat is an investigational oral aldosterone synthase inhibitor being developed for uncontrolled or resistant hypertension and related comorbidities including chronic kidney disease and obstructive sleep apnea. The company said its program includes Phase 3 Launch-HTN and Phase 2 Advance-HTN, and described lorundrostat as well tolerated in those trials with reductions in systolic blood pressure.